A close look at current γδ T-cell immunotherapy

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Gamma delta (γδ) T cells are increasingly recognized for their potential in adoptive T-cell immunotherapy.
• Their unique antitumor and major histocompatibility complex (MHC)-independent functions make them attractive candidates for cancer treatment.
• Despite growing interest, significant knowledge gaps and limited clinical data persist regarding γδ T cells.

Purpose of the Study:

• To provide a comprehensive overview of γδ T-cell applications in immunotherapy.
• To systematically review the current landscape of γδ T-cell immunotherapy.
• To highlight clinical performance, ongoing trials, and pharmaceutical relevance of γδ T cells.

Main Methods:

• Systematic literature review.
• Analysis of published clinical trial data.
• Evaluation of γδ T-cell roles in cancer treatment and pharmaceutical development.

Main Results:

• γδ T cells exhibit potent antitumor activities in preclinical and early clinical settings.
• A growing number of clinical trials are investigating γδ T-cell therapies for various cancers.
• The pharmaceutical industry is actively exploring γδ T cells for novel therapeutic strategies.

Conclusions:

• γδ T cells represent a promising frontier in adoptive T-cell immunotherapy for cancer.
• Further clinical investigation and data collection are crucial to fully realize their therapeutic potential.
• Understanding the multifaceted role of γδ T cells is vital for advancing cancer treatment.